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The emergence of treatment resistant sub-clones is a key feature ofrelapse in multiple myeloma. Therapeutic attempts to extend remis-sion and prevent relapse include maximizing response and the use of
maintenance therapy. We used whole exome sequencing to study the
genetics of paired samples taken at presentation and at relapse  from 56
newly diagnosed patients, following induction therapy, randomized to
receive either lenalidomide maintenance or observation as part of the
Myeloma XI trial. Patients included were considered high risk, relapsing
within 30 months of maintenance randomization. Patients achieving a
complete response had predominantly branching evolutionary patterns
leading to relapse, characterized by a greater mutational burden, an altered
mutational profile, bi-allelic inactivation of tumor suppressor genes, and
acquired structural aberrations. Conversely, in patients achieving a partial
response, the evolutionary features were predominantly stable with a sim-
ilar mutational and structural profile seen at both time points. There were
no significant differences between patients relapsing after lenalidomide
maintenance versus observation. This study shows that the depth of
response is a key determinant of the evolutionary patterns seen at relapse.
This trial is registered at clinicaltrials.gov identifier: 01554852.
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ABSTRACT
Introduction
Multiple myeloma (MM) results from the malignant transformation of a normal
plasma cell and has a mutational load which lies in an intermediate position
between genetically simple malignancies, such as chronic myelogenous leukemia,
and the more complex solid cancers.1,2 As such, MM provides an excellent model
system through which to understand the mutational and evolutionary processes
underlying disease relapse. MM is a genetically diverse condition, which is mani-
fested by variations in clinical outcome even in uniformly treated populations.3,4
The treatment of newly diagnosed (ND) MM has improved over the last decade
following the introduction of immunomodulatory drugs and proteasome inhibi-
tion, which, together with autologous stem cell transplantation, have increased the
median overall survival from three to eight years.5-7 However, patients frequently
relapse, and to improve outcomes further, strategies have
been designed to eliminate the residual clonal cells that
mediate relapse.8-10 In this context, an important strategy
has been the use of maintenance therapy with lenalido-
mide.11-13 This agent is well tolerated and has a bifunction-
al mode of action directly killing the tumor cells and
enhancing the immune response to the malignant plasma
cells that is mediated by directing Aiolos and Ikaros to the
proteasome for degradation.14-17  
Understanding the features of residual cells that lead to
relapse is an important challenge; however, this is technical-
ly difficult, especially in patients who have achieved strin-
gent complete responses. One way of understanding the
characteristics of cells in remission is to study the character-
istics of cells at relapse. Previous studies of the genetic fea-
tures of paired presentation and relapse samples have
shown that, after intensive chemotherapy, bi-allelic loss of
tumor suppressor genes, in particular TP53, and the dereg-
ulation of MYC by structural chromosomal changes are
important features.18 In addition to mutational change, sub-
clonal structure also varies at relapse and three main pat-
terns have been described; branching, linear and shifting
patterns of clonal dominance18-23 (Table 1). Such analyses
have not, however, studied uniformly treated patients for
whom the depth of response or treatment information is
available. To address the impact of maintenance and
response depth on mutational patterns and clonal structure
at relapse, we performed whole exome sequencing (WES)
on paired presentation and relapse samples from 56
NDMM patients, 30 of whom had received lenalidomide
maintenance and 26 who had not.  All were treated at first
presentation with a triple induction regimen containing an
immunomodulatory agent, cyclophosphamide, and dexam-
ethasone, making this the largest analysis of genetic evolu-
tion in a uniformly treated series of MM patients to date.
Methods 
Samples were selected from NDMM patients enrolled into the
Myeloma XI trial (clinicaltrials.gov identifier: 01554852) for whom
adequate DNA volumes were available.24 The study was under-
taken after written informed consent from patients and ethical
approval was obtained from the Oxfordshire Research Ethics
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Table 1. Previous studies assessing clonal evolution in myeloma.
Study                                       N. of patients                    Disease status                         Technique                                             Findings
Keats et al.                                                28                                     Presentation                                     Array                                                         Three major 
Blood  201219                                                                                        vs. Relapse                                       CGH                                   evolutionary mechanisms identified:
                                                                                                                                                                                                                                      1. Genetically stable
                                                                                                                                                                                                                                    2. Linear evolution
                                                                                                                                                                                                                               3. Heterogeneous clonal 
                                                                                                                                                                                                                             mixtures and shifting 
                                                                                                                                                                                                                               predominant clones.
Magrangeas et al.                                    24                                     Presentation                                 SNP array                                             Branching evolution
Leukaemia 201320                                                                               vs. Relapse                                                                                                  outlined as a cause
                                                                                                                                                                                                                       for relapse in one-third of patients. 
                                                                                                                                                                                                                                   The remaining patients 
                                                                                                                                                                                                                               displayed  linear and stable 
                                                                                                                                                                                                                                      pathways to relapse.
Bolli et al.                                                  67                                     Presentation                                 NGS/SNP                                         Linear, branching, stable 
Nat Commun                                                                                       vs. Relapse                                       array                                                and differential clonal
201421                                                                                                                                                     and cytogenetics                         evolutionary responses described. 
                                                                                                                                                                                                                               Description of kataegis and 
                                                                                                                                                                                                                                   somatic hypermutation.
Melchor et al.                                            6                                      Presentation                            NGS and single                                       Linear and branching
Leukaemia 201423                                                                               vs. Relapse                                cell analysis                           evolution shown at a single cell level.
Kortum et al.                                            25                                     Presentation                           NGS gene panel                               Use of a targeted sequencing 
Ann Hematol 201522                                                                           vs. Relapse                                                                                   panel to demonstrate gain and loss 
                                                                                                                                                                                                                            of  significantly mutated genes 
                                                                                                                                                                                                                               confirming clonal evolution.
Weinhold et al.                                         33                                     Presentation                             NGS and GEP                          Mutational load increases at relapse
Blood                                                                                                    vs. Relapse                                                                                     in association with enrichment of
201618                                                                                                                                                                                                             driver gene mutations and bi-allelic 
                                                                                                                                                                                                                                              TSG events. 
                                                                                                                                                                                                                           Branching evolution as the main 
                                                                                                                                                                                                                            mechanism leading to relapse.
CGH: comparative genomic hybridization; SNP: single nucleotide polymorphism; NGS: next generation sequencing; GEP: gene expression profiling; TSG: tumor suppressor
genes.
Committee (MREC 17/09/09, ISRCTN49407852). A nested case
control analysis was performed on 56 patients who received either
lenalidomide maintenance (n=30) or  were observed  (n=26) and
subsequently relapsed25,26 (Online Supplementary Figure S1). All
patients included had phenotypical high-risk disease, defined as
relapse within 30 months of maintenance randomization, irre-
spective of classical genetic risk status and best response. The
median time from trial entry to relapse was 19 months, notably
shorter than the progression-free survival (PFS) reported in the
Myeloma XI trial of 35.9 and 32.9 months for patients treated
with lenalidomide and thalidomide induction, respectively.27
Response was determined using International Myeloma Working
Group (IMWG) criteria and a near complete response  (nCR),
defined as no detectable paraprotein, a normal light chain ratio,
but where immunofixation and or bone marrow sampling was
not performed or if immunofixation was positive. Prior to relapse,
21% (12 of 56) achieved a CR, 21% (12 of 56) a nCR, 42% (23 of
56) a very good partial response (VGPR), and 16% (9 of 56) a par-
tial response (PR). To determine the impact of response on the
genetic landscape at relapse we grouped patients according to the
best response achieved prior to relapse, complete responders
(CR/nCR) and non-complete responders (VGPR/PR). Clinical char-
acteristics were well matched between the maintenance groups
(Table 2). Patients' characteristics according to induction regimen
were also well matched (Online Supplementary Table S1). 
DNA was isolated from plasma cells following selection using
CD138+ MACSorting (Miltenyi Biotech, Bisley, UK) from bone
marrow aspirate samples. Control DNA was obtained from
peripheral blood samples. Libraries for WES were prepared using
the SureSelectQXT sample prep kit and the SureSelect Clinical
Research Exome kit (Agilent), with additional baits covering the
immunoglobulin and MYC loci, as previously described.28   Paired-
end sequencing was performed to a median sequencing depth of
122x for tumor samples and 58x for controls using a HiSeq2500
(Illumina). Single nucleotide variants, including those of tumor
suppressor genes and oncogenes, were determined using Strelka
(v.1.0.14) and MuTect.29,30 The distribution of mutant alleles deter-
mined by the variant allele frequency (VAF) was mapped using the
R package SciClone.31 Cancer clonal fractions (CCF) were calculat-
ed for all mutations and plotted using Kernal density estimation to
infer clonal structure at presentation and relapse.32
Copy number was assessed using both multiplexed ligation-
J.R. Jones et al.
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Figure 1. The mutational profile at presentation and relapse. (A) Recurrent mutations in myeloma and mutations within the genes associated with immunomodu-
latory agent action. The number of patients with these mutations at presentation, relapse, and at both time points is shown (dotted line denotes level of 10%). (B)
Summary of mutations gained and lost at relapse. New mutations at relapse were seen in PRDM1, TP53, NF1, TET2, EGFR, MYC, DDB1, CRBN, and FAF 1 (red bars).
Loss of mutations in FANCA, DIS3, FAM46C, BRAF and CDH2 were noted at relapse (blue bars). Mutations in NRAS, KRAS, and SLC16A1 were gained and lost at
relapse. (C) Mutational profile for each patient at presentation and relapse. Maintenance strategy and best response prior to relapse is shown. The gain and loss of




dependant probe amplification (MLPA) (SALSA MLPA P425-B1
multiple myeloma probemix, MRC Holland, Amsterdam, the
Netherlands) and the bioinformatics assessment tool Sequenza
(v.2.1.2).33,34 Paired MLPA and Sequenza data was available for 90
of 112 (80%) tumor samples, with a consensus between MLPA
and Sequenza being seen in 85 of 90 samples (94%).  For the five
patients for whom a mismatch was observed, Sequenza was used
to call the copy number profile. Translocations were determined
using MANTA (v.0.29.3).35 For 46% (51 of 112) of patient samples,
translocations involving the immunoglobulin heavy chain (IGH)
were also assessed using multiplexed qRT-PCR.36  A consensus
between MANTA and qRT-PCR was observed in 84% (43 of 51).
In the eight patients for whom a mismatch was seen, the integra-
tive genomics viewer (IGV) was used to confirm or exclude the
translocation. All suspected bi-allelic copy number abnormality
(CNA) events were confirmed by manual interrogation of BAM
files using IGV. Bi-allelic inactivation was also called in patients
with evidence of a non-synonymous mutation with mono-allelic
loss or a single mutation with a VAF of ≥80%. A summary of the
methods, bioinformatics tools and filters used to complete this
analysis is available in Online Supplementary Figure S2. 
Statistical analysis was performed using GraphPad Prism v.7.01
and R v.3.2.1. P=0.05 (two-sided) was considered statistically sig-
nificant. Wilcoxon matched-pairs signed rank tests were conduct-
ed to determine significance between paired data sets, including
the mutational load at presentation/relapse and PFS according to
maintenance allocation, depth of response, and induction treat-
ment. Fisher exact test was used to determine differences between
two nominal variables, including the change in mutational profile
from presentation to relapse and the evolutionary mechanism
leading to relapse.  
Results
Relapse is characterized by a change in mutational
spectrum  
At presentation, genes mutated in >10% of patients
were NRAS (23%, n=13), KRAS (23%, n=13), and DIS3
(13%, n=7) ((Figure 1A and B)). At relapse, TP53 was also
seen in >10% of patients (11%, n=6). We examined genes
that have previously been shown to be recurrently mutat-
ed in myeloma, including tumor suppressor genes, epige-
netic modifiers, and genes within the RAS, NFκB and
apoptosis pathways, the results of which are summarized
(Figure C).18,28,37-44 Non-synonymous mutations were seen
in one or more of these genes in 79% (44 of 56) of patients
at presentation and 80% (45 of 56) at relapse. Importantly,
gain and/or loss of one or more of these lesions at relapse
was seen in 37% of patients (21 of 56), with 21% (12 of
56) of patients gaining a new lesion, 11% (6 of 56) losing
a lesion, and 5% (3 of 56) both gaining and losing lesions.
The most common new mutations at relapse were KRAS
and PRDM1, both seen in 5% of patients (3 of 56), and
NRAS and TP53, each seen in 4% (2 of 56). However,
mutations in KRAS and NRASwere just as likely to be lost
Maintenance, response status, and subclonal structure at MM relapse
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Figure 2. The proportion of patients with a change in the profile of mutations known to be recurrent in myeloma or important in immunomodulatory mechanism
of action at relapse. (A) The proportion of all patients (n=56) with a change in the profile of recurrent mutations at relapse. The majority of complete remission (CR)
series patients had a change in the mutational profile at relapse, 67% (16 of 24) versus 25% (8 of 32) of non-CR patients (Wilcoxon matched pairs, P=0.003). (B)
The proportion of observation patients (n=26) with a change in the profile of recurrent mutations at relapse. Only 19% (3 of 16) of non-CR patients under observation
had a change in the profile of mutations at relapse, compared to 70% (7 of 10) of CR patients under observation (P=0.02). (C) The proportion of lenalidomide main-
tenance patients (n=30) with a change in the profile of recurrent mutations at relapse. The same pattern of mutational profile change was seen in the lenalidomide
maintenance patients, with 64% (9 of 14) of the CR patients having a mutational profile change at relapse compared to 31% of non-CR patients (P=0.14). 
A B C
at relapse, with 5% (3 of 56) of patients losing KRAS
mutations and 4% (2 of 56) losing NRAS (Figure 1B). The
most commonly mutated pathway was the RAS-MAPK
pathway, with mutations of one or more of NRAS, KRAS,
BRAF, NF1, and EGFR being seen in 57% (33 of 56) of
patients at some point during the disease course. Loss of
one or more of these mutations was noted in 9% (5 of 56)
of patients at relapse while new mutations were seen in
13% (7 of 56). The majority of these new mutations were
clonal (CCF>80%) and all had a CCF >20% (range, 0.29-
1) (Online Supplementary Figure S3). The results of these
mutational studies are consistent with there being impor-
tant changes in subclonal structure at relapse, rather than
the simple accumulation of new mutations.  The profile of
mutations at presentation and relapse in patients who
received lenalidomide or thalidomide induction was well
matched (Online Supplementary Table S2). 
Acquired structural change is a frequent feature of
relapse
We interrogated regions of recurrent CNA that are
known to be associated with prognosis: 1p32.3
(FAF1/CDKN2C), 1p12 (FAM46C), 13 (RB1), 14q (TRAF3),
and 17p (TP53). Copy number loss of ≥1 of these regions
was seen in 63% (35 of 56) of patients at presentation and
59% (33 of 56) at relapse (Online Supplementary Figure S4).
There was an evident change in the profile at relapse, with
regions of loss seen at presentation returning to a diploid
status in 9% (5 of 56) of patients while new losses were
seen in 13% (7 of 56). Once again, these features are  con-
J.R. Jones et al.
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Figure 3. Number of mutational clus-
ters at presentation and relapse. (A)
For all 56 patients, the number of
mutational clusters was similar at
presentation and relapse. The same
pattern was seen irrespective of main-
tenance strategy (B and C) or depth of
response (D and E). This suggests
that a change in clonal number is not




sistent with an alteration in subclonal structure and a
change in the nature of the dominant clone observed  at
relapse. 
Gain(1q) was the most common new event at relapse,
occurring in 13% (7 of 56) patients. Secondary transloca-
tions to chromosome 8q, the site of MYC, also occurred
more frequently at relapse, increasing from 21% (12 of 56)
to 27% (15 of 56) (Online Supplementary Table S3).45
Consistent with translocations to MYC being late events,
five patients had evidence of two separate MYC translo-
cations at relapse. All patients with gain(1q) or tMYC at
presentation had evidence of the lesion at relapse, illus-
trating the driver status. 
Bi-allelic inactivation of tumor suppressor genes located
at sites of recurrent CNA are likely to be relevant media-
tors of relapse. We show that bi-allelic inactivation events
of RB1, TRAF3, and TP53 are important with 18% (10 of
56) of patients having evidence of bi-allelic inactivation of
≥1 gene at relapse, in comparison to 14% (8 of 56) at pres-
entation. One patient harboring both a TP53mutation and
del(17p) at presentation lost evidence of the del(17p) at
relapse, but maintained bi-allelic inactivation via expan-
sion of a different subclone characterized by a TP53muta-
tion which had a higher CCF at relapse (0.55 vs. 0.83).
Relapse following a complete response is 
characterized by a greater mutational load and a
change in genetic profile
Patients achieving a CR had a significantly higher non-
synonymous mutational load at relapse, with a median of
59 mutations compared to 40 at presentation (P<0.001).
Non-CR patients had a similar mutational load at relapse,
with a median of 39 mutations at both time points
(P=0.63). Similar patterns were also seen in patients
receiving or not receiving lenalidomide maintenance
(Online Supplementary Table S4). 
By comparing the profile of known recurrently mutated
genes, we show that 67% (16 of 24) of CR cases had a
change in mutational profile at relapse compared to only
25% (8 of 32) of non-CR cases (P=0.003) (Figure 2A); these
findings were a feature of both the observation and
lenalidomide maintenance series (Figure 2B and C).
Consistent with the mutation profile changes described,
gain and loss of the structural lesions del(1p), del(13),
del(14), del(17p), gain (1q), and tMYC at relapse was more
common in the CR series, with 42% (10 of 24) of patients
having a change in the profile of these aberrations com-
pared to  28% (9 of 32) of non-CR patients (Online
Supplementary Figure 5S). The changes in mutational load
Maintenance, response status, and subclonal structure at MM relapse
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Table 2. Series characteristics.
                                                                                          Whole series                                                  Maintenance randomization
                                                                                              (% of all)                                  Lenalidomide                                  Observation
                                                                                                                                              (% of group)                                   (% of group)
N. of patients                                                                                                56                                                          30                                                              26
Median age                                                                                                    68                                                          67                                                              69
Gender                                                                                                                                                                                                                                          
Male                                                                                                         28 (50)                                                 13 (43)                                                    15 (58)
Female                                                                                                     28 (50)                                                 17 (57)                                                    11 (42)
Pathway                                                                                                                                                                                                                                         
TE                                                                                                              22 (39)                                                 11 (37)                                                    11 (42)
TNE                                                                                                          34 (61)                                                 19 (63)                                                    15 (58)
Induction                                                                                                                                                                                                                                      
Thalidomide                                                                                           29 (52)                                                 15 (52)                                                    14 (48) 
Lenalidomide                                                                                         27 (48)                                                 15 (56)                                                    12 (44)
Best response                                                                                                                                                                                                                             
CR series (CR/nCR)                                                                             24 (43)                                                 14 (47)                                                    10 (38)
Non-CR series (VGPR/PR)                                                                  32 (57)                                                 16 (53)                                                    16 (62)
Median maintenance duration (months, range)                           10 (1-27)                                              10 (1-27)                                                  9 (1-22)
Median number of maintenance cycles (range)                                n/a                                                    7 (1-28)                                                       n/a
Median PFS (months, range)                                                             19 (8-51)                                              19 (8-51)                                                 19 (8-34)
Presentation ISS                                                                                                                                                                                                                         
I                                                                                                                 13 (23)                                                  5 (17)                                                      8 (31)
II                                                                                                                21 (38)                                                 12 (40)                                                     9 (35)
III                                                                                                              21 (38)                                                 12 (40)                                                     9 (35)
Missing                                                                                                      1 (2)                                                     1 (3)                                                             
Cytogenetic risk*                                                                                                                                                                                                                        
High risk                                                                                                  20 (36)                                                 12 (40)                                                     8 (31)
Ultra-high risk                                                                                         7 (13)                                                   5 (13)                                                       2 (8)
*High risk defined as one of t(4;14), t(14;16), t(14;20), gain(1q), and del(17p). Ultra-high risk defined as two lesions.TE: transplant eligible; TNE: transplant ineligible; CR: com-
plete response; nCR: near CR; VGPR: very good partial response; PR: partial response; PFS: progression-free survival; ISS: International Staging System; n/a: not applicable.
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Figure 4. The evolutionary patterns seen leading to relapse. (A) Branching: branching evolution was the predominant mechanism seen and was characterized both
by the gain and loss of mutational clusters at relapse. The cancer clonal fractions (CCF) for all coding mutations using kernel density estimation for a typical patient
(left) is shown and reveals the presence of a new dominant PRDM1 (CCF 1.0) containing clone at relapse only (each dot represents a mutation). In addition, a clone
containing CHD2 (CCF 0.91 presentation only)  is lost at relapse while a clone containing NRAS remained dominant at presentation (CCF 1.0) and relapse (CCF 0.99).
(Right) Illustration of the branching evolutionary process using the same patient. Prior to treatment, there are a number of competing sub-clones, but as a result of
effective therapy, clonal extinction occurs leading to a genetic bottleneck. This leads to the emergence of a new clonal structure at relapse; in this case the loss of
a dominant CHD2 clone, the gain of a PRDM1 clone, and a stable NRAS clone. In addition, the emergence of a new DDB1 mutation was seen within a minor clone
with a CCF of 0.21. (B) Linear: linear evolution was seen in 20% of patients, characterized by the gain of mutations at relapse but no evidence of clonal loss. The
KDE plot is displayed and shows the emergence of a new clonal PRDM1mutation at relapse with a CCF of 1.0. (Right) Over time, successive generations of daughter
cells acquire aberrations making them genetically distinct; in this example, we see the emergence of a new PRDM1 mutation. (C) Stable progression:  KDE plot (left)
showing a typical patient with stable progression, revealing a preserved clonal structure at both time points, with CCF values for all mutations remaining consistent
at both time points. The CHD2mutation was present within a dominant clone at presentation and relapse with a CCF of 0.83 and 0.87, respectively. Stable evolution
was a characteristic of patients achieving a non-complete remission (non-CR), and in particular a partial remission (PR). These patients appeared to have a treatment
resistant disease status and therefore the emergence of the same clonal structure was seen at relapse as had been seen at disease onset; in this case, with a CHD2
dominant clone at both time points (right). (D) Stable with loss was seen in one patient and kernel density estimation (right) revealed the presence of a predominantly
preserved clonal structure at relapse with clusters containing TRAF3 and LTB present with similar CCF values at both points. There was evidence of the loss of a
cluster of mutations at relapse, suggestive of clone loss (circled). The evolutionary process is shown. Treatment sensitive clone(s) are eliminated but the resistant





could not be linked to a change in the number of clones
predicted by SciClone clustering, where a median number
of seven clones was seen at relapse in both the CR and
non-CR series (Figure 3). The same findings were noted
for all 56 patients and when analyzed according to main-
tenance strategy. No patient had evidence of the loss or
gain of >2 mutational clusters at relapse, further suggest-
ing that a change in the number of clones is not a major
cause for change in the mutational load (Online
Supplementary Table S5).  
Lenalidomide maintenance has no impact on the
mutational profile at relapse
There was no specific mutational, copy number or
structural feature which characterized patients who
received lenalidomide maintenance compared to  observa-
tion patients. Of patients who received lenalidomide
maintenance, 83% (25 of 30) had a mutation in one or
more of the recurrently mutated myeloma genes at some
point during the disease course compared to 85% (22 of
26) of observation patients. Gain and/or loss of one or
more mutation at relapse, including those in genes impli-
cated in the mechanism of action of an immunomodulato-
ry agent, were seen in 43% (13 of 30) of patients receiving
lenalidomide maintenance  and 35% (9 of 26) of the obser-
vation patients (Figure 1B). 
We did not identify a mutational signal consistent with
the selection of clones carrying mutations associated with
acquired resistance to lenalidomide. Five patients had
mutations in DDB1 (n=2), SLC16A1 (n=2), and CRBN
(n=1), but these were not confined to the cases of lenalido-
mide maintenance, nor were they seen exclusively at
relapse (Figure 1B). Mutations in other genes linked to the
mechanism of action of lenalidomide, including regulator
of cullins 1, cullin-4A, Ikaros, Aiolos, and Basigin, were
not found at presentation or relapse in any patient.14,46-48
Mutations in MYC and IRF4, transcription factors known
to be down-regulated in response to immunomodulation,
were seen in 2% (n=1) and 4% (n=2) of patients, respec-
tively. However, consistent with an acquired mutation
having a possible role in drug resistance, we identified one
patient who had been exposed to eight months of
lenalidomide maintenance and achieved flow cytometric
minimal residual disease (MRD) negativity (minimum
5x105 cells interrogated) and who then went on to develop
a novel CRBN mutation (p.Cys326Gly) at relapse; this is
consistent with the emergence of resistance due to muta-
tion at the immunomodulatory molecule binding site. The
mutation was also present in a dominant clone, with a
CCF of 0.71, further suggesting its presence may have
impacted on the fitness of the tumor in relation to pres-
sure from the  immunomodulatory treatment (Online
Supplementary Figure S6).  
Branching evolution is the predominant process 
leading to relapse, particularly in patients achieving 
a deep treatment response
We observed three main evolutionary patterns at
relapse: branching, linear, and stable. Branching evolution
was characterized by both gain and loss of mutational
clusters and was the predominant pattern, seen in 66% (37
of 56) of all cases (Figure 4A). Linear evolution character-
ized only by the gain of mutations at relapse was seen in
20% (11 of 56) of cases (Figure 4B). The remaining 14% (8
of 56) had either the same mutational profile at both time
points, and were classified as stable progression (n=7), or
displayed a loss of a mutational cluster at relapse, classi-
fied as stable progression with clone loss (n=1)  (Figure 4C
and D). There was no significant impact of induction or
maintenance lenalidomide on the evolutionary pattern
seen at relapse (Online  Supplementary Figure S7). 
We show that the depth of treatment response is the
most important determinant of the evolutionary pattern
seen at relapse. Although branching evolution was domi-
Maintenance, response status, and subclonal structure at MM relapse
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Figure 5. The evolutionary patterns seen leading to relapse according to the depth of treatment response. (A) The evolutionary mechanism leading to relapse for
the complete remission (CR) and non-CR series. Stable evolution was only seen in the non-CR patients (Fishers exact test, P=0.008). Branching evolution was the
predominant mechanism leading to relapse in both CR and non-CR patients, with linear evolution also occurring, but in a smaller proportion of patients. (B) The evo-
lutionary mechanism leading to response according to the depth of response. Over half (56%) of the patients who achieved a partial response (PR) as their best
response prior to relapse progressed via a stable mechanism (P=0.002). A smaller proportion of very good partial response (VGPR) patients displayed stable pro-
gression (13%). Branching evolution was dominant, and was seen in 75% of nCR patients and 67% of CR patients.
A B
*PR stable/non-stable vs. non-PR stable/non-stable (Fisher’s exact test)
nant in both the CR and non-CR series, stable progression
was only seen in the non-CR series, (25%, 8 of 32, vs. 0%,
0 of 25; P=0.008) (Figure 5A). Breaking down the non-CR
series further showed that stable progression was pre-
dominantly associated with a PR (56%, 5 of 9 of PR; 13%,
3 of 23 of VGPR patients). No CR or nCR patients (0 of 24)
had evidence of stable progression, with all patients
showing branching or linear evolution (P=0.002) (Figure
5B).  Consistent with a deep response being synonymous
with a change in clonal architecture, 86% (6 of 7) of
patients who achieved an MRD-negative state relapsed via
a branching mechanism and 14% (1 of 7) via linear evolu-
tion. The type of evolution leading to relapse had no
impact on the time to relapse or overall survival (Online
Supplementary Table S6). 
Discussion
This study shows that an increase in mutational load,
altered mutational profile, accumulation of deleterious
structural lesions [particularly tMYC and gain(1q)], and a
change in copy number profile are key molecular features
of relapse. The depth of response to treatment has a sig-
nificant impact on both the genetic landscape and the evo-
lutionary patterns seen at relapse, with an increased muta-
tional load being predominantly associated with the
achievement of a CR. We also note that relapse from CR
is associated with an altered mutational profile, with 63%
(15 of 24) of the CR patients having evidence of loss or
gain of known recurrently mutated genes in comparison
to only 25% (8 of 32) of non-CR patients (P=0.006). This
pattern was also seen for CNA and structural variants,
with del(17p), tMYC, gain(1q), and loss of tumor suppres-
sor gene regions, including CDKN2C, FAF1, FAM46C,
RB1, and TRAF3, being seen more frequently in the
patients relapsing after CR. 
It has been shown that the progression through the mul-
tistep transformation of MM is associated with an
increased mutational load. This is well illustrated by stud-
ies that have compared monoclonal gammopathy of
undetermined significance, MM, and plasma cell
leukemia. Our results are consistent with this observation,
and we clearly show that an increased mutational load is
an important factor in early disease progression following
a good response to treatment.49,50 Similar findings are
observed in other cancer types where a greater mutational
load is associated with a more aggressive disease status,
for example, lung cancer in smokers compared to non-
smokers, and in malignant melanoma.51,52 
A variety of subclonal patterns, including branching, lin-
ear, and stable patterns, are seen at relapse (Figure 4A-D).
The pattern of clonal change is most consistent with the
hypothesis that branching evolutionary pathways are the
predominant mechanism underlying relapse, especially if
spatial variation is taken into account. Treatment can be
seen as causing an evolutionary bottleneck, particularly in
patients who achieve a deep treatment response, provid-
ing a selective pressure for the emergence of pre-existent
resistant clones. Importantly, these branching patterns and
increased genetic damage in the clonal cells are hallmarks
of effective treatment and achievement of deep responses.
In contrast, the stable patterns seen in non-CR patients are
most consistent with microenvironmental change, possi-
bly as a consequence of the presence of treatment resistant
dominant clones at disease onset. This stable pattern is
reminiscent of the results seen in the progression of smol-
dering MM to MM, where the emergence of new muta-
tions is infrequent, yet there is a profound change in clin-
ical behavior.
Mechanistically, relapse in the setting of effective thera-
py that results in the achievement of a CR is occurring
either due to the emergence of low-level sub-clones that
are undetectable at presentation, but which are selected
for by treatment, or as a result of the acquisition of new
mutations, albeit less likely given the short duration of
remission. It may also be that the differences seen are the
result of sampling bias, as previously shown by our group,
although this is less likely given that all biopsies were
obtained from the pelvis.53  The pattern of results seen
with eradication of dominant clones and emergence of
low-level clones with different pattern of mutation, and its
association with CR, supports the concept that treatment
can result in subclonal eradication. These findings high-
light the therapeutic importance of achieving a CR to
eradicate dominant clones present at the initiation of ther-
apy. Supporting this as a therapeutic aim, we have recent-
ly shown that high-risk patients achieving a molecular CR
have very significantly improved 5-year survival rates.54 
The results show that, even in MRD-negative CR, low-
level resistant subclones remain, and therapeutic strategies
need to be designed to address them. We believe this
work supports the current best practice strategy of using
different treatment regimens at successive relapses and
shows why this approach is successful. We show that
early relapse is either due to innate treatment resistance,
requiring no change in the clonal structure, or due to a
change of clonal architecture in response to effective ther-
apy. Both mechanisms are consistent with a disease state
at relapse that is resistant to the initial therapies used. This
knowledge supports the use of combination regimens at
relapse, incorporating agents with differing mechanisms
of action to those used at presentation. This will be ana-
lyzed in a planned comparator series of patients who
achieve long-term remission in the trial. Our work here
does, however, provide new insights into the mechanisms
of early relapsing disease, revealing a different mechanism
in those who achieve a deep therapeutic response and
those who do not.  
Interestingly, a recent study looking at non-small cell
lung cancer has shown that mutational load may direct
treatment choices, whereby the use of immunotherapy
was associated with a longer and durable remission in
patients with a greater mutational load at presentation.55
Therefore,  as our understanding of myeloma biology
increases, information such as mutational load may guide
specific treatment modalities in the future. The use of
lenalidomide maintenance is one of the first clinical strate-
gies to address the residual cells that remain following ini-
tial treatment. Using this approach, we did not see a signal
of any adverse impact on the clonal cells as a result of this
therapy. In particular, we did not see a signal for selection
of mutations that could confer resistance to lenalidomide
either at presentation or at relapse. Previous studies have
suggested that such mutations may exist and could be rel-
atively frequent in cell lines and heavily pre-treated
patients, but in this study of newly diagnosed patients
they were rare.56 However, we do describe a patient who
received eight months of maintenance treatment, achiev-
ing an MRD-negative CR who did relapse with a new
J.R. Jones et al.
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CRBN mutation. It is likely that the mutation occurred by
chance, but that, in true Darwinian fashion, in the pres-
ence of lenalidomide, it conferred a survival advantage to
the malignant cells harboring it. Recent analyses indicating
that prolonged exposure to lenalidomide is not linked to
an increased incidence of second primary hematologic
malignancies when used in combinations excluding oral
melphalan may be supported by a lack of evidence of
mutagenesis leading to treatment resistance in this work,
although it is acknowledged that larger analyses using
patients with prolonged remissions are required.24,57 It is
important to note that the patients studied here relapsed
early and that  they were selected because of this charac-
teristic, as it had previously been suggested that exposure
to lenalidomide could enhance progression of such cases
post maintenance. However, we did not find any evidence
to support such a hypothesis. 
It does remain important to evaluate the impact of
maintenance on low-risk cases who are long-term sur-
vivors, a question not addressed in this study. In addition,
we acknowledge that clonal structure may be further
assessed using single cell analysis. However, for the
moment, the challenges of obtaining individual malignant
plasma cells from large series of patients at multiple dis-
ease time points has proved to be a significant barrier. In
this series of patients, however, we do see evidence of par-
allel evolution, as previously described using single cell
technology, further validating the clonal changes
described here.23 An example is seen in a patient with bi-
allelic inactivation of TP53 at presentation characterized
by del(17p) and TP53mutation, but only the presence of a
TP53 mutation at relapse. In this case the clone with
del(17p) was no longer detectable at relapse, suggesting it
was treatment sensitive and/or out-completed by a more
aggressive treatment insensitive clone harboring a TP53
mutation that had expanded following treatment, con-
firmed by a higher CCF at relapse (0.55 vs. 0.83). 
In this group of high-risk early-relapsing patients, we
show that relapse is a result of the dynamic interplay of
evolutionary processes based on the capacity of clonal
cells to adapt to their bone marrow microenvironment as
a result of new mutations, copy number change, and the
selective pressure of the treatment used. Specifically, the
depth of response is a critical feature that impacts the evo-
lutionary patterns seen at relapse, rather than the use of
lenalidomide maintenance. 
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